European white paper: oropharyngeal dysphagia in head and neck cancer

Baijens, Laura W. J., Walshe, Margaret, Aaltonen, Leena-Maija, Arens, Christoph, Cordier, Reinie, Cras, Patrick, Crevier-Buchman, Lise, Curtis, Chris, Golusinski, Wojciech, Govender, Roganie, Eriksen, Jesper Grau, Hansen, Kevin, Heathcote, Kate, Hess, Markus M., Hosal, Sefik, Klussmann, Jens Peter, Leemans, C. René, MacCarthy, Denise, Manduchi, Beatrice, Marie, Jean-Paul, Nouraei, Reza, Parkes, Claire, Pflug, Christina, Pilz, Walmari, Regan, Julie, Rommel, Nathalie, Schindler, Antonio, Schols, Annemie M. W. J., Speyer, Renee, Succo, Giovanni, Wessel, Irene, Willemsen, Anna C. H., Yilmaz, Taner and Clavé, Pere (2021) European white paper: oropharyngeal dysphagia in head and neck cancer. European Archives of Oto-Rhino-Laryngology, 278 (2). pp. 577-616. ISSN 0003-9195

Preview	Text (Final published version) Baijens2021_Article_EuropeanWhitePaperOropharyngea.pdf - Published Version Available under License Creative Commons Attribution 4.0. Download (1MB) | Preview
Preview	Text (Advanced online version) Baijens2020_Article_EuropeanWhitePaperOropharyngea.pdf - Published Version Available under License Creative Commons Attribution 4.0. Download (1MB) | Preview

Abstract

Purpose: To develop a European White Paper document on oropharyngeal dysphagia (OD) in head and neck cancer (HNC). There are wide variations in the management of OD associated with HNC across Europe. Methods:
Experts in the management of specific aspects of OD in HNC across Europe were delegated by their professional medical and multidisciplinary societies to contribute to this document. Evidence is based on systematic reviews, consensus-based position statements, and expert opinion. Results:
Twenty-four sections on HNC-specific OD topics.
Conclusion:
This European White Paper summarizes current best practice on management of OD in HNC, providing recommendations to support patients and health professionals. The body of literature and its level of evidence on diagnostics and treatment for OD in HNC remain poor. This is in the context of an expected increase in the prevalence of OD due to HNC in the near future. Contributing factors to increased prevalence include aging of our European population (including HNC patients) and an increase in human papillomavirus (HPV) related cancer, despite the introduction of HPV vaccination in various countries. We recommend timely implementation of OD screening in HNC patients while emphasizing the need for robust scientific research on the treatment of OD in HNC. Meanwhile, its management remains a challenge for European professional associations and policymakers.

Actions (login required)

View Item

Downloads